Improving treatment of children with acute lymphoblastic leukemia in developing countries through technology sharing, collaboration and partnerships

References

• Pui CH. Toward a total cure for acute lymphoblastic leukemia. J Clin Oncol 2011;27:5121-3
   Google Scholar
• Rivera GK, Pinkel D, Simone JV, et al. Treatment for acute lymphoblastic leukemia - 30 years’ experience at St. Jude Children’s Research Hospital. N Engl J Med 1993;329:1289-95
   PubMed Web of Science ®Google Scholar
• Ribeiro RC, Steliarova-Foucher E, Magrath I, et al. Baseline status of paediatric oncology care in ten low-income or mid-income countries receiving My Child Matters support: a descriptive study. Lancet Oncol 2008;9:721-9
   PubMed Web of Science ®Google Scholar
• Bhakta N, Martiniuk AL, Gupta S, et al. The cost effectiveness of treating paediatric cancer in low-income and middle-income countries: a case-study approach using acute lymphoblastic leukemia in Brazil and Burkitt lymphoma in Malawi. Arch Dis Child 2013;98:155-60
   PubMed Web of Science ®Google Scholar
• Liu Y, Chen J, Tang Y, et al. Cost of childhood acute lymphoblastic leukemia care in Shanghai, China. Pediatr Blood Cancer 2009;53:557-62
   PubMed Web of Science ®Google Scholar
• Antillon F, Rossi E, Molina AL, et al. Nutritional status of children during treatment for acute lymphoblastic leukemia in Guatemala. Pediatr Blood Cancer 2013;60:911-15
   PubMed Web of Science ®Google Scholar
• Magrath I, Steliarova-Foucher E, Epelman S, et al. Improving cancer care for children and young people 2. Paediatric cancer in low-income and middle-income countries. Lancet Oncol 2013;14:e104-6
   PubMedGoogle Scholar
• Sullivan R, Kowalczyk J, Agarwal B, et al. Improving cancer care for children and young people 4. New policies to address the global burden of childhood cancers. Lancet Oncol 2013;14:e125-35
   PubMedGoogle Scholar
• Hopkins J, Burns E, Eden T. International twinning partnerships: an effective method of improving diagnosis, treatment and care for children with cancer in low-middle income countries. J Cancer Policy 2013;1:e8-e19
   Google Scholar
• Pinkel D. Five year follow-up of “total therapy” of childhood lymphocytic leukemia. JAMA 1971;216:246-54
   Google Scholar
• Pui CH. Prophylactic cranial irradiation: going, going, gone. Lancet Oncol 2009;10:932-3
   PubMed Web of Science ®Google Scholar
• Masera G, Baez F, Biondi A, et al. North-South twinning in paediatric hemato-oncology: the La Mascota programme, Nicaragua. Lancet 1998;352:1923-6
   PubMed Web of Science ®Google Scholar
• Magrath I, Santa V, Advani S, et al. Treatment of acute lymphoblastic leukaemia in countries with limited resources; lessons from use of a single protocol in India over a twenty year period. Eur J Cancer 2005;41:1570-83
   PubMed Web of Science ®Google Scholar
• Hunger SP, Sung L, Howard SC. Treatment strategies and regimens of graduated intensity for childhood acute lymphoblastic leukemia in low-income countries: a proposal. Pediatr Blood Cancer 2009;52:559-65
   PubMed Web of Science ®Google Scholar
• Stary J, Zimmermann M, Campbell M, et al. Intensive chemotherapy for childhood acute lymphoblastic leukemia: results of the randomized intercontinental trial ALL IC- BFM 2002. J Clin Oncol 2013;3:174-84
   Google Scholar
• Ribeiro RC, Pui CH. Treatment of acute lymphoblastic leukemia in low-and middle-income countries: challenges and opportunities. Leuk Lymphoma 2008;49:373-6
   PubMed Web of Science ®Google Scholar
• Day SW, Segovia L, Viveros P, et al. The Latin American Center for Pediatric Oncology Nursing Education: development, implementation, and accomplishments. Cancer Nurs 2013;36(5):340-5
   PubMed Web of Science ®Google Scholar
• Howard SC, Campana D, Coustan-Smith E, et al. Development of a regional flow cytometry center for diagnosis of childhood leukemia in Central America. Leukemia 2005;19:323-5
   PubMedGoogle Scholar
• Coustan Smith E, Ribeiro RC, Stow P, et al. A simple flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcome Blood. 2006;108:97-102
   Google Scholar
• Howard SC, Pedrosa M, Lins M, et al. Establishment of a pediatric oncology program and outcomes of childhood acute lymphoblastic leukemia in a resource-poor area. JAMA 2004;291:2471-5
   PubMed Web of Science ®Google Scholar
• Chauvenet AR, Martin PL, Devidas M, et al. Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from Children’s Oncology Group Study 9201. Blood 2007;110:1105-11
   PubMed Web of Science ®Google Scholar
• Borowitz MJ Devidas M, Hunger SH, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children’s Oncology Group study. Blood 2008;111:5477-85
   PubMedGoogle Scholar
• Moghrabi A, Levy DE, Asselin B, et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood 2007;109:896-904
   PubMed Web of Science ®Google Scholar
• Moricke A, Reiter A, Zimmermann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood 2008;111:4477-89
   PubMed Web of Science ®Google Scholar
• Arico M, Valsecchi MG, Rizzari C, et al. Long-term results of the AIEOP-ALL-95 trial for childhood acute lymphoblastic leukemia: insight on the prognostic value of DNA index in the framework of Berlin-Frankfurt-Muenster-based chemotherapy. J Clin Oncol 2008;26:283-9
   PubMed Web of Science ®Google Scholar
• Pui CH, Campana D, Pei D, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med 2009;360:2730-41
   PubMed Web of Science ®Google Scholar
• Vora A, Goulden N, Wade R, et al. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial. Lancet Oncol 2013;14:199-209
   PubMed Web of Science ®Google Scholar
• Pui CH. Reducing delayed intensification therapy in childhood ALL. Lancet Oncol 2013;14:178-9
   PubMedGoogle Scholar
• Ness KK Armenian SH, Kadan-Lottick N, Gurney JG. Adverse effects of treatment in childhood acute lymphoblastic leukemia: general overview and implications for long-term cardiac health. Expert Rev Hematol 2011;4(2):185-97
   PubMedGoogle Scholar